First Patient Dosed in the Phase I/II Study of Umecrine Mood’s Candidate Drug for Premenstrual Dysphoric Disorder

Published: May 23, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

STOCKHOLM – May 23, 2013. Umecrine Mood AB announced today that dosing has been initiated in a randomized Phase I/II study of UC1010 for the treatment of patients with premenstrual dysphoric disorder (PMDD). Umecrine Mood is part of the Karolinska Development portfolio.

Help employers find you! Check out all the jobs and post your resume.

Back to news